Full Text of PDF (481k)
Article in Japanese
Abstract
Case Report
A case of pembrolizumab-induced secondary sclerosing cholangitis in a patient with lung adenocarcinoma
Takumi Kanokogia Muneyuki Sekiyaa Chiaki Katoa Takanori Mukozub Kazutoshi Shibuyac Kazuma Kishia
aDepartment of Respiratory Medicine, Toho University Omori Medical Center
bDepartment of Gastroenterology and Hepatology, Toho University Omori Medical Center
cDepartment of Diagnostic Pathology, Toho University Omori Medical Center
ABSTRACT
A 54-year-old man diagnosed with lung adenocarcinoma and receiving combination therapy with pembrolizumab and chemotherapy presented with fever and liver dysfunction. Findings from magnetic resonance cholangiopancreatography and liver biopsy indicated a diagnosis of pembrolizumab-induced secondary sclerosing cholangitis. Although liver function improved during treatment with ursodeoxycholic acid, bezafibrate, and steroid, it worsened during tapering of the steroid. Immune checkpoint inhibitor-induced secondary sclerosing cholangitis is a rare immune-related adverse event that is often difficult to treat.
KEYWORDS
Lung cancer Sclerosing cholangitis Immune checkpoint inhibitor (ICI) Pembrolizumab Immune-related adverse event
Received 29 Sep 2021 ／ Accepted 3 Dec 2021
AJRS, 11(2): 92-97, 2022
Copyright © The Japanese Respiratory Society All Rights Reserved.